cancer sequencing

Feb 17, 2022

Mass General, Lunaphore Technologies to Develop Test to Predict PARP Inhibitor Response

Dec 14, 2021

BostonGene Partners with NEC to Offer Tumor Portrait Tests Internationally

Apr 2, 2021

Illumina Parries FTC Challenge to Grail Acquisition With Deals for Competing Customers
Premium

Mar 16, 2021

Illumina, Geneseeq Technology to Collaborate on IVD Cancer Testing Kits in China

Feb 25, 2021

Natera Revenues Grow 35 Percent in Q4

Feb 25, 2021

NantHealth Q4 Revenues Flat From Year Ago

Feb 17, 2021

Exact Sciences Sketches Out Strategy for End-to-End Cancer Testing With Ashion Acquisition
Premium

Feb 2, 2021

Congenica, Gabriel Precision Oncology Partner on Clinical Interpretation for Somatic Cancer Testing

Jan 13, 2021

At JPM, Natera CEO Lays Out Growth Potential for NIPT, Transplant, Cancer Testing

Jan 11, 2021

Illumina CEO Discusses Pan-Cancer IVD Assay, CDx Collaborations at JP Morgan

Dec 1, 2020

Illumina, PierianDx Expand Partnership on Cancer Panel Test Reporting

Nov 5, 2020

NantHealth Q3 Revenues Tick Up Slightly

Oct 14, 2020

PierianDx, Pillar Biosciences Partner to Streamline NGS Cancer Analysis

Sep 21, 2020

Grail Deal Will Enable Illumina to Expand From Tech Innovator to Diagnostics Provider

Sep 21, 2020

JP Morgan Downgrades Illumina to Neutral on Grail Deal

Sep 16, 2020

Illumina's Stock Falls 9 Percent on Grail Acquisition Rumors

Sep 11, 2020

Natera Prices $250M Public Stock Offering

Aug 6, 2020

NantHealth Q2 Revenues Decline 12 Percent

Aug 6, 2020

Adaptive Biotechnologies Receives Expanded FDA Clearance for ClonoSeq MRD Assay

Jul 29, 2020

Sema4 Raises $121M in Series C Financing Round